Ukunyanga i-HIV ne-Triumeq

Ipilisi yokudibanisa ekhethwe kwiTradio-Line yokuqala

I-Triumeq iyisilwanyana esisigxina esisigxina esisodwa sosuku, esisodwa esisetyenziswe kunyango lwe-HIV. I-Abacavir, lamivudine, ne-dolutegravir, i-Triumeq yamkelwe yi-US Food and Drug Administration ngo-Agasti 2014 kwaye yonyulwa izidakamizwa ezikhethiweyo kwiyeza lokuqala lokuqala kwiSebe lezeMpilo kunye neNkonzo zoLuntu.

UkuPhenywa kokuPhambi kokuPhathwa

Ngaphambi kokuba uqalise i-Triumeq, kufuneka uhlolwe ukuba ubone ukuba une-HLA-B * ye-genetic mutation 5701.

Ukuba ukwenza, awuyi kukwazi ukuthatha i-Triumeq njengoko ubeka umngcipheko wokuphendulwa kwe- abacavir ebangelwayo .

I-Triumeq ingasetyenziselwa abantu abaneengxaki zeengtso. Ukuze ugweme utywala olunxulumene neziyobisi, iimvavanyo zentsholongwane kufuneka zenziwe phambi kokuba unyangwe unyango.

Isistim nokuLawula

I-Triumeq isetyenziswe kwipilisi yomlomo eline-abacavir 600mg, i-lamivudine 300mg, ne-dolutegravir 50mg. Imilinganiselo ephakanyisiweyo yipilisi enye imihla ngemihla, ithathwe kunye okanye ngaphandle kokutya. I-Triumeq yi-tablet ye-oblong e-white-oblong engxenyeni enye "nge-572 Tri."

Iziphumo eziPhakathi

I-Triumeq ithathwa njengekhuselekile xa isetyenziswe njengoko iyalathwayo kodwa ingabangela iziphumo zecala kwezinye. Uninzi lwale miphumo yecala luyanyamezela kwaye ngokuqhelekileyo isisombululo sodwa ngeveki. Okuqhelekileyo (okwenzeka ubuncinane kweepesenti ezimbini zamatyala) kukuba:

Ukungqinelana kunye nokuHlangana

I-Tikosyn (dofetilide) , esetyenziselwa unyango lwe- arrhythmia (intliziyo engavumelekanga), iyaphikiswa ukusetyenziswa kunye ne-Triumeq.

Thetha nogqirha wakho ngokufaka endaweni ye Triumeq okanye iTikosyn ukuba ufuna unyango kuzo zombini imeko

Ukuze ugweme ukusebenzisana kweziyobisi, cebisa ugqirha ukuba uthatha nawaphi na amayeza alandelayo:

Imilinganiselo ingadinga ukulungiswa okanye indawo efunyenweyo.

Ukuqwalasela

Xhalela ugqirha wakho ngokukhawuleza ukuba ufumana impendulo emva kokuqala i-Triumeq. Funa unonophelo lwengxamiseko xa unomphefumlo ohamba kunye nomkhuhlane, iintlungu okanye iintlungu ezixhamliweyo, iintsholongwane, iingxaki zokuphefumla, okanye ukuvuvukala kwamehlo, ubuso okanye umlomo.

I-Triumeq kufuneka ithathe iiyure ezimbini ngaphambi kweyure okanye ezintandathu emva kokuthatha i-aluminium okanye i-magnesium-based based antacid okanye i-laxative, isongezelelo sesinyithi, isongezelelo se-calcium, imithi exutyiweyo okanye i- sucralfate esetyenziselwa unyango lwezilonda zezilonda.

Yazisa ugqirha wakho nayiphi na imeko yesibindi onokuyenza ngaphambi kokuba uqalise i-Triumeq. I-Triumeq inokubangela ukunyuka kweempawu, ngakumbi kubantu abane- hepatitis B okanye i- hepatitis C. Xa uqaliswe unyango, i-enzymes yesibindi kufuneka ihlolwe njengenxalenye yomvavanyo wegazi lomntu.

> Imithombo:

> Ulawulo lweZiko lokuTya kunye neDrug. "Amaphuzu aphambili ekuchazeni ulwazi: TRIUMEQ (abacavir, dolutegravir, kunye ne-lamivudine) amacwecwe okusetyenziswa ngomlomo." Silver Spring, eMaryn; Agasti 2014.

> I-Weller, S .; Chen, S; Borland, J .; okqhubekayo. "I-bioequivalence ye-dolutegravir, abacavir, kunye ne-lamivudine i-dose ene-tablet ehlanganisiweyo kunye nesiphumo sokutya." I-Journal ye-Immune Deficiency Syndrome. Agasti 1,2014; 66 (4): 393-398. INGXELO: 10.1097 / QAI.0000000000000193.